BioSpectrum ASIA EDITION
the business of Bio & Health Sciences

FDA approves Procainamide HCL Injection, USP for treatment of ventricular arrhythmias

27 October 2017 | News

Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening.

Singapore - Nexus Pharmaceuticals (a US based healthcare company) announced the immediate availability in the United States of Procainamide HCL Injection, USP. Nexus Pharmaceuticals' Procainamide HCL Injection, USP is available as a multi dose vial containing 1,000 mg per 2 mL (500 mg/mL) or as a multi dose vial containing 1,000 mg per 10 mL (100 mg/mL) and is an AP Rated generic equivalent. Procainamide HCL Injection, USP is currently listed on the FDA Drug Shortage Database.

"The introduction of Procainamide HCL Injection, USP further illustrates Nexus Pharmaceuticals' commitment to meeting market needs and shortages in the short term, while broadening the availability of effective generic products for the long term," said Mariam Darsot, President of Nexus Pharmaceuticals Inc.

Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided.